Core Viewpoint - The recent announcement by the National Medical Products Administration (NMPA) regarding the revision of the isotretinoin capsule instructions highlights the growing concerns over the drug's side effects, particularly its potential impact on mental health and sexual function, amidst a surge in acne treatment demand during the winter break [1][2]. Group 1: Drug Overview and Usage - Isotretinoin, commonly referred to as "EVA," has gained popularity as an acne treatment among young people, often promoted on social media for its effectiveness while downplaying its side effects [2][3]. - The drug is available in both oral capsule and topical cream forms, and it has been a key medication for treating severe nodular acne since its introduction in the U.S. and Europe in 1982 [3][4]. Group 2: Side Effects and Regulatory Actions - The revised instructions for isotretinoin now include a comprehensive list of adverse reactions, such as endocrine, digestive, mental, and reproductive issues, emphasizing the need for careful monitoring of patients [2][6]. - Reports of adverse reactions globally include 394 cases of depression and 37 suicide incidents in the U.S. from 1982 to 2000, and 14 cases of sexual dysfunction in the UK from 1985 to 2017 [4][5]. - The Australian Therapeutic Goods Administration has mandated that all isotretinoin products include new safety information regarding emotional changes and risks of sexual dysfunction by April 2025 [5]. Group 3: Recommendations and Patient Management - Medical professionals emphasize that isotretinoin should only be used under the supervision of qualified healthcare providers, and many mild acne cases can be treated with safer alternatives [5][6]. - The NMPA's warning encourages patients to consider safer, appropriate, and effective treatment options rather than risking the use of isotretinoin [5].

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the drug instructions for Montelukast sodium formulations, highlighting potential neuropsychiatric adverse reactions across all age groups, including severe symptoms like depression and suicidal tendencies, which may persist if the medication is not discontinued [1][2]. Group 1: Drug Safety and Revisions - The revised drug instructions will prominently feature a black box warning indicating that neuropsychiatric adverse reactions have been reported in patients of all ages taking Montelukast, including severe reactions such as depression and suicidal tendencies [2]. - The updated instructions will also include a new adverse reaction: stuttering, alongside other neuropsychiatric symptoms such as aggression, anxiety, and hallucinations [2][4]. - The revision aims to enhance public safety regarding medication use and to remind healthcare professionals to be vigilant in identifying and managing these risks [4]. Group 2: Clinical Insights and Usage - Montelukast is commonly used for treating asthma, allergic cough, and allergic rhinitis, and has been on the market since 1998, with several generics approved in China following the expiration of its patent [4]. - Despite the potential for adverse reactions, experts emphasize that Montelukast remains an important medication for asthma treatment, and patients should not panic or discontinue use without consulting a physician [5]. - The recommended dosages for children include 4 mg and 5 mg formulations, with specific guidelines for age groups to minimize risks associated with overdose [5].

Core Viewpoint - The National Medical Products Administration (NMPA) of China has announced a revision of the prescribing information for Montelukast formulations, mandating the inclusion of explicit warnings regarding neuropsychiatric adverse reactions, including depression and suicidal tendencies [1][2]. Group 1: Regulatory Changes - The revision is based on the results of adverse drug reaction monitoring and assessment [1]. - All Montelukast formulations, including tablets, chewable tablets, granules, and orally dissolving films, are subject to this revision, with the latter three being specifically for pediatric use [2]. - The NMPA requires all marketing authorization holders of Montelukast to revise the prescribing information by March 12, 2026, and to replace the labels of all manufactured products within nine months after the filing [3]. Group 2: Market Context - Montelukast, developed by Merck & Co., was first approved in 1998 and is a selective leukotriene receptor antagonist indicated for the prevention and long-term treatment of asthma in children aged 2 to 14 years [2]. - Following the expiration of its patent, various generic versions have emerged globally, with over 60 approved marketing numbers in China from manufacturers such as Qilu Pharmaceutical, Tianyu Pharmaceutical, and others [2]. - In 2023, Montelukast's sales in Chinese public medical institutions exceeded 1 billion yuan, ranking among the top five chemical drugs for obstructive airway diseases [2].

Core Viewpoint - The National Medical Products Administration (NMPA) of China has announced a revision of the prescribing information for Montelukast formulations to enhance public safety regarding medication use, particularly concerning neuropsychiatric adverse reactions [2][4]. Group 1: Regulatory Changes - The NMPA's announcement includes a unified revision of the prescribing information for Montelukast formulations, which encompasses Montelukast sodium tablets, chewable tablets, granules, and orally dissolving films [2]. - The revised prescribing information will include warnings about neuropsychiatric adverse reactions reported across all age groups, including severe reactions such as depression and suicidal tendencies [4]. Group 2: Clinical Implications - Montelukast, developed by Merck and first approved in 1998, is a selective leukotriene receptor antagonist primarily used for treating asthma and allergic rhinitis [7]. - The drug is commonly used in children due to concerns about the side effects of inhaled corticosteroids, although it may cause side effects such as drowsiness, mental excitement, nightmares, and even depressive tendencies [7]. - Medical professionals are advised to conduct a thorough benefit/risk analysis based on the newly revised prescribing information when selecting medications for patients [9].

Core Viewpoint - The National Medical Products Administration (NMPA) has announced a unified revision of the instructions for Montelukast formulations to enhance public medication safety, highlighting the potential neuropsychiatric adverse reactions associated with the drug [1] Group 1: Regulatory Changes - The NMPA's decision is based on the evaluation of adverse drug reactions, aiming to ensure safer medication use among the public [1] - The revised warning will include reports of neuropsychiatric adverse reactions across all age groups, including severe reactions such as depression and suicidal tendencies [1] Group 2: Patient Guidance - The new instructions recommend that if neuropsychiatric symptoms occur during treatment with Montelukast, the medication should be discontinued and medical attention sought [1] - Patients and caregivers are advised to be vigilant for neuropsychiatric adverse reactions and to inform healthcare providers if related symptoms arise during the medication period [1]

Core Viewpoint - The National Medical Products Administration (NMPA) of China has announced a unified revision of the product instructions for Montelukast formulations to enhance public medication safety, highlighting potential neuropsychiatric adverse reactions associated with the drug [3][9]. Group 1: Drug Safety and Revisions - The revised instructions will include warnings about neuropsychiatric adverse reactions reported across all age groups, including severe reactions such as depression and suicidal tendencies [3][4]. - Patients experiencing neuropsychiatric symptoms during Montelukast treatment are advised to discontinue use and seek medical attention [3][4]. Group 2: Market and Usage Insights - Montelukast is a common asthma treatment drug, initially developed by Merck and approved for sale in foreign markets in 1998. Following the expiration of its patent in China, several generic versions have been approved [8]. - In 2023, Montelukast's sales in Chinese public medical institutions exceeded 1 billion yuan, ranking among the top five obstructive airway disease medications [8]. - The drug is frequently used in children due to concerns about the side effects of inhaled corticosteroids, although it can cause side effects such as drowsiness and potential depressive tendencies [8]. Group 3: Regulatory and Clinical Implications - The NMPA's requirement for the revision aligns with previous warnings issued by the U.S. FDA regarding the drug, indicating a proactive approach to drug safety [9]. - The drug's marketing authorization holders are expected to conduct in-depth research on the mechanisms of newly identified adverse reactions and implement effective measures for safety training and communication [9].

Core Viewpoint - The National Medical Products Administration (NMPA) of China has announced a unified revision of the product instructions for Montelukast formulations to enhance public medication safety, following reports of neuropsychiatric adverse reactions associated with the drug [1][2]. Group 1: Regulatory Changes - The NMPA's announcement includes a requirement for the product instructions to warn about neuropsychiatric adverse reactions reported across all age groups, including severe reactions such as depression and suicidal tendencies [1]. - The revised instructions will advise that if neuropsychiatric symptoms occur during treatment, the medication should be discontinued and medical attention sought [1][3]. Group 2: Market Context - Montelukast is a common asthma treatment drug, originally developed by Merck and approved for use in 1998. With the expiration of its patent in China, several generic versions have been approved for sale [2]. - In 2023, Montelukast's sales in Chinese public medical institutions exceeded 1 billion yuan, ranking it among the top five obstructive airway disease medications [2]. Group 3: Clinical Insights - Montelukast is primarily used as an adjunct treatment for asthma, particularly in children, who often prefer it over inhaled corticosteroids due to concerns about side effects [2]. - While some patients may experience side effects such as drowsiness or mood disturbances, most can recover after discontinuation of the drug, with few experiencing long-term effects [2].